CYCNCyclerion Therapeutics
About Cyclerion Therapeutics
Cyclerion Therapeutics (NASDAQ:CYCN) focuses on discovering, developing, and commercializing innovative medicines for the treatment of serious diseases. The company is engaged in advancing a diverse pipeline of treatments that address central nervous system (CNS) disorders, including cognitive impairment and neurodegenerative conditions. Their objective is to leverage their unique scientific platform to bring breakthrough treatments to patients in need, aiming to improve lives through novel therapeutics. With a commitment to science and innovation, Cyclerion Therapeutics is dedicated to pushing the boundaries of medicine to tackle some of the most challenging health issues.
What is CYCN known for?
Snapshot
Public US
Ownership
2018
Year founded
14
Employees
Massachusetts, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of Cyclerion Therapeutics
- Development of treatments targeting the soluble guanylate cyclase (sGC) pathway for various diseases including heart, lung, and kidney disorders.
- Research on central nervous system (CNS) therapies, focusing on cognitive impairment associated with schizophrenia and other neurological conditions.
- Investigation into treatments for serious orphan diseases by leveraging the sGC stimulator platform to address unmet medical needs.
- Initiatives aimed at advancing cardiovascular health, such as potential therapies for heart failure and hypertension through the modulation of sGC.
- Exploration of novel therapeutic approaches in metabolic disorders, including diabetes and obesity, by targeting key pathways influencing metabolism.
- Pursuit of the development of first-in-class treatments for genetic diseases affecting the nervous system, emphasizing rare and severe conditions.
Cyclerion Therapeutics executive team
- Dr. Regina M. Graul Ph.D.CEO, President & Director
- Ms. Rhonda M. Chicko CPAChief Financial Officer